Assessing nucleic acid integrity, purity, and quantity during critical stages of your RNA- and DNA-based vaccine production delivers accurate and reliable sample quality data, so you can make informed decisions throughout your workflow. 

In this in-depth presentation, Agilent product manager Kyle Luttgeharm gives an overview of the three Fragment Analyzer systems and how they are integrated into the vaccine production process to enable robust and reliable nucleic acid sample quality assessment. In addition, you will hear detailed explanations and see lab-based examples for each QC check performed during your:

• mRNA vaccine workflow, including methods for IVT mRNA product screening, poly(A) tail addition, and final product quality assessment
• DNA vaccine workflow, including target DNA isolation and amplification, plasmid purification, and final product analysis

Access the presentation and gain exclusive information to help you boost your vaccine development.